These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3017590)

  • 21. [Selective resistance of human neuroblastoma cells to a vaccine strain of poliomyelitis virus].
    Tol'skaia EA; Kolesnikova MS; Drozdov SG; Agol VI
    Dokl Akad Nauk SSSR; 1989; 305(4):987-9. PubMed ID: 2546724
    [No Abstract]   [Full Text] [Related]  

  • 22. [The use of immunomodulators to enhance postvaccinal immunity to experimental poliomyelitis].
    Bondarenko VI; Zadorozhnaia VI; Buraia TA; Gritsenko LN
    Mikrobiol Z; 1995; 57(6):41-5. PubMed ID: 8714398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thermostability of poliovirus and measles vaccines.
    Melnick JL
    Dev Biol Stand; 1996; 87():155-60. PubMed ID: 8854012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a new combined inactivated DPT-polio vaccine.
    Drucker J; Soula G; Diallo O; Fabre P
    Dev Biol Stand; 1986; 65():145-51. PubMed ID: 3030861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccines based on recombinant antigen strategies.
    Minor P
    Dev Biol (Basel); 2001; 105():189-94. PubMed ID: 11763327
    [No Abstract]   [Full Text] [Related]  

  • 26. [Monoclonal antibodies against Brunhilde strain of poliovirus type I].
    Tang EH; Jian YQ; Wen YL; Lin JY; Guo R
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Apr; 6(2):150-2. PubMed ID: 6100481
    [No Abstract]   [Full Text] [Related]  

  • 27. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.
    Mas Lago P; Ramon Bravo J; Andrus JK; Comellas MM; Galindo MA; de Quadros CA; Bell E
    Bull World Health Organ; 1994; 72(2):221-5. PubMed ID: 8205641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C; Shi H; Zhou J; Liang Y; Xu H
    Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant polioviruses as candidate strains of oral poliovaccines.
    Nomoto A
    Dev Biol Stand; 1995; 84():123-7. PubMed ID: 7796944
    [No Abstract]   [Full Text] [Related]  

  • 31. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Schild GC
    Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigenic sites on type 2 poliovirus.
    Patel V; Ferguson M; Minor PD
    Virology; 1993 Jan; 192(1):361-4. PubMed ID: 7685967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cross-sectional sero epidemiological prevalence of polio virus antibodies post-immunization with three doses of TOPV.
    Tswana SA; Berejena C; Moyo SR; Mudyarabikwa O
    Cent Afr J Med; 1994 Nov; 40(11):303-5. PubMed ID: 7859270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Revaccination by oral monovalent poliovaccine type 3 (author's transl)].
    Srámová H; Teplý V; Bernatziková V
    Cesk Epidemiol Mikrobiol Imunol; 1981 Mar; 30(2):95-100. PubMed ID: 6261973
    [No Abstract]   [Full Text] [Related]  

  • 35. Determination of poliovirus-specific IgA in saliva by ELISA tests.
    Ivanov A; Dragunsky E; Ivanova O; Rezapkin G; Potapova S; Chumakov K
    J Virol Methods; 2005 Jun; 126(1-2):45-52. PubMed ID: 15847918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current concepts of the antigenic structure and attenuation mechanisms of the poliomyelitis virus].
    Gendon IuZ
    Vopr Virusol; 1988; 33(4):389-92. PubMed ID: 2461613
    [No Abstract]   [Full Text] [Related]  

  • 37. Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccine.
    Taffs RE; Enterline JC; Rusmil K; Muhilal ; Suwardi SS; Rustama D; Djatnika ; Cobra C; Semba RD; Cohen N; Asher DM
    Bull World Health Organ; 1999; 77(6):484-91. PubMed ID: 10427933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India.
    Grassly NC; Jafari H; Bahl S; Durrani S; Wenger J; Sutter RW; Aylward RB
    J Infect Dis; 2009 Sep; 200(5):794-801. PubMed ID: 19624278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccine-derived poliovirus type 1, 2, 3 strains in Japan.
    Iwai M; Takizawa T; Nakayama T; Matsuura K; Yoshida H; Hasegawa S; Obara M; Horimoto E; Kurata T; Horie H
    Scand J Infect Dis; 2008; 40(3):247-53. PubMed ID: 17907043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Isolates of poliovirus vaccine and immune response to different doses of oral polio vaccine].
    Más Lago P; Díaz J; Díaz Gonzalez M; Goyenechea Hernández A; Barrio Olivera J; Fonseca Quintana M; Morier Díaz L; Sarmiento Pérez L; Palomera Puente R
    Rev Cubana Med Trop; 2005; 57(2):111-9. PubMed ID: 17966580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.